NASDAQ:SNOA

Sonoma Pharmaceuticals Q3 2026 Earnings Results & Report

Sonoma Pharmaceuticals logo
$0.72 -0.09 (-10.83%)
Closing price 04:00 PM Eastern
Extended Trading
$0.72 -0.01 (-0.69%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sonoma Pharmaceuticals missed analyst expectations on both earnings and revenue in its Q3 2026 results, released February 10, 2026. The company reported EPS of -$0.35 versus the -$0.29 consensus estimate, while revenue of $4.35 million fell short of the $5.47 million estimate by $1.13 million.

Earnings Announcement Details

Quarter
Q3 2026
Time
Before Market Opens

Sonoma Pharmaceuticals EPS Results

Actual EPS
-$0.35
Consensus EPS
-$0.29
Beat/Miss
Missed by -$0.06
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Sonoma Pharmaceuticals Revenue Results

Actual Revenue
$4.35 million
Expected Revenue
$5.47 million
Beat/Miss
Missed by -$1.13 million
YoY Revenue Growth
N/A

Conference Call Resources

Sonoma Pharmaceuticals Q3 2026 Earnings FAQ

Sonoma Pharmaceuticals (NASDAQ:SNOA) reported earnings of -$0.35 per share for Q3 2026, missing the consensus estimate of -$0.29. The report was announced on Tuesday, February 10, 2026.

Sonoma Pharmaceuticals reported revenue of $4.35 million for Q3 2026, against a consensus estimate of $5.47 million.

Sonoma Pharmaceuticals Earnings Headlines

Management just bought 2.8 million shares
Management just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 in one quarter. Institutions own about 83% of shares, including BlackRock's 32 million shares worth $716 million and Vanguard's 48 million shares worth nearly $1.1 billion. A new multi-year deal with Palantir adds an AI-driven edge to this energy producer's operations.tc pixel
See More Sonoma Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sonoma Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sonoma Pharmaceuticals and other key companies, straight to your email.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals (NASDAQ:SNOA) develops and markets products based on its stabilized hypochlorous acid technology for human and animal health. Its product portfolio includes solutions and gels for wound care, skin conditions, eye care and other hygiene applications.

The company’s offerings include Microcyn-branded products, which are used in areas such as wound management and dermatology, as well as products for veterinary care. Sonoma sells its products through commercial partners and distributors in the United States and international markets.

The company was formerly known as Oculus Innovative Sciences and adopted the Sonoma Pharmaceuticals name in 2016. Its business has since focused on developing and commercializing hypochlorous acid-based products for healthcare and related markets.

View Sonoma Pharmaceuticals Profile